you attend the first study visit after agreeing to participate. during this visit, the study team records your medical history, performs a physical examination, and collects blood and imaging tests to establish a baseline for your condition.

the results of the baseline tests are reviewed to confirm that you meet the study criteria. these assessments serve as reference points for later comparison of safety and response to the treatment.

you receive an intravenous injection of ng-350a in a dose of 3 ml. the medication is given through a vein using a syringe. the injection is performed in the clinic under the supervision of the study staff.

shortly after the ng-350a injection, you receive an infusion of pembrolizumab (brand name keytruda) at a dose of 400 mg. the drug is mixed as a solution for infusion and delivered slowly into a vein over a period of time.

following each medication administration, you are observed in the clinic for a period of time. vital signs such as blood pressure, heart rate, and temperature are checked, and you are asked about any new symptoms. this monitoring helps identify any immediate side effects.

throughout the study, you return to the clinic for scheduled visits. at each visit, the study team repeats safety assessments, collects blood samples, and may perform additional imaging to evaluate how the tumour is responding. the timing of these visits follows the study protocol.

if additional doses of ng-350a or pembrolizumab are required, they are given in the same manner as the first administration, using the same 3 ml injection for ng-350a and the 400 mg infusion for pembrolizumab.

when the planned treatment period ends, you undergo a final set of assessments. these include a physical exam, laboratory tests, and imaging studies to determine the overall safety profile and any effect on the tumour.

the results are recorded, and you are informed about the next steps for continuing routine medical care.